Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech company. Here is why now is as good a time as any to "buy low" when it comes to this stock. Vertex Pharmaceuticals ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Vertex Pharmaceuticals (VRTX) closed the latest trading day at $402.70, indicating a +0.84% change from the previous session's end. This change outpaced the S&P 500's 0.43% loss on the day. At the ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (VRTX ... Elsewhere, the Dow gained 0.91%, while the tech-heavy Nasdaq added 1.35%. The the stock of drugmaker has fallen by 12.22% in the past month, lagging the Medical ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective trimmed by Barclays from $509.00 to $418.00 in a ...

Vertex (NASDAQ:VERX – Free Report) had its price target boosted by Stifel Nicolaus from $52.00 to $58.00 in a research report report published on Wednesday morning,Benzinga reports.They ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global ...